AstraZeneca to acquire Modella AI to speed oncology drug research

Core Insights - AstraZeneca has agreed to acquire Modella AI, a Boston-based company, highlighting the pharmaceutical industry's increasing reliance on artificial intelligence for drug discovery [1] Company Summary - AstraZeneca is expanding its capabilities by integrating artificial intelligence through the acquisition of Modella AI [1] - Modella AI specializes in leveraging AI technology to enhance the drug discovery process, which aligns with industry trends [1] Industry Summary - The pharmaceutical industry is increasingly adopting artificial intelligence to accelerate the discovery of new drugs, indicating a shift towards more technology-driven approaches [1]